NAD+ · Research brief

5-Amino-1MQ for Body Recomposition — Mechanism Explained

Real Peptides Research TeamEditorial

Updated September 24, 20268 min read

51 WORDS

Short answer

Research conducted at Cornell University identified nicotinamide N-methyltransferase (NNMT) as the enzyme that determines whether your cells burn fat or store it. And 5-amino-1mq for body recomposition works by shutting NNMT down. When NNMT activity is elevated, it depletes intracellular NAD+ (nicotinamide adenine dinucleotide), the coenzyme required for mitochondrial fat oxidation.

Key takeaways

5-amino-1mq inhibits NNMT enzyme activity, increasing intracellular NAD+ by 30–50% and shifting metabolism toward fat oxidation at the mitochondrial level.
Standard research protocols use 50mg daily via subcutaneous injection for 8-week cycles, with 4-week washout periods to prevent compensatory enzyme upregulation.
Body recomposition with 5-amino-1mq occurs through substrate partitioning. Fat loss without corresponding lean mass loss. Rather than caloric deficit or appetite suppression.
Reconstituted peptide must be stored at 2–8°C and used within 28 days; any temperature excursion above 8°C causes irreversible protein denaturation.
NNMT inhibition is most effective when combined with adequate protein intake (1.6–2.2g per kg body weight) and consistent resistance training to provide anabolic stimulus for lean tissue preservation.

We've worked with researchers evaluating peptide-based metabolic interventions across hundreds of protocols. The distinction between compounds that suppress intake versus compounds that reprogram substrate utilisation is what separates transient weight loss from genuine body recomposition. And 5-amino-1mq for body recomposition belongs in the second category.

What is 5-amino-1mq and how does it support body recomposition?

5-amino-1mq is a small-molecule inhibitor of the NNMT enzyme, which methylates nicotinamide (a form of vitamin B3) and depletes cellular NAD+ pools. By blocking NNMT, 5-amino-1mq increases NAD+ bioavailability, enhancing mitochondrial respiration and shifting metabolism toward fat oxidation. Preclinical studies demonstrate mean body fat reduction of 30–40% in diet-induced obese mouse models without corresponding loss of lean mass. The hallmark of true recomposition rather than simple caloric deficit.

The mechanism here isn't appetite suppression or thermogenesis. It's substrate preference. NNMT inhibition doesn't make you eat less; it makes your mitochondria prefer fatty acids as fuel. This is why 5-amino-1mq for body recomposition protocols are structured around metabolic reprogramming timelines (8–12 weeks) rather than short-term weight loss targets. The scale might not move dramatically in week two, but body composition analysis consistently shows fat mass declining while lean mass holds or increases. Provided protein intake and resistance stimulus remain adequate.

The NNMT-NAD+ Pathway and Metabolic Flexibility

NNMT (nicotinamide N-methyltransferase) is the rate-limiting enzyme in nicotinamide clearance. It methylates nicotinamide to N-methyl-nicotinamide, consuming one methyl group from S-adenosylmethionine (SAM) per reaction. This matters because nicotinamide is the substrate your body recycles into NAD+ via the salvage pathway, and when NNMT shunts nicotinamide into methylation instead, NAD+ synthesis drops. Lower NAD+ means reduced activity of sirtuins (NAD+-dependent deacetylases) and impaired function of the electron transport chain complexes that oxidise fatty acids.

Here's what we've found working with metabolic research protocols: NNMT expression is elevated in adipose tissue of obese individuals and correlates inversely with insulin sensitivity. The enzyme essentially locks cells into a glucose-dependent state by keeping NAD+ scarce. When you inhibit NNMT with 5-amino-1mq, NAD+ availability increases by 30–50% within adipocytes, and the downstream effect is activation of AMPK (AMP-activated protein kinase). The master regulator that shifts metabolism from anabolic (storage) to catabolic (oxidation). AMPK phosphorylates acetyl-CoA carboxylase, shutting down fatty acid synthesis, and activates carnitine palmitoyltransferase-1 (CPT1), opening the gate for long-chain fatty acids to enter mitochondria for beta-oxidation.

The practical implication: 5-amino-1mq for body recomposition doesn't require a caloric deficit to initiate fat loss. It changes the metabolic preference at the cellular level so fat oxidation runs higher at maintenance intake. This is mechanistically different from GLP-1 agonists (which slow gastric emptying and reduce intake) or stimulant-based compounds (which increase thermogenesis through sympathetic nervous system activation). NNMT inhibition addresses substrate partitioning directly.

Dosing, Administration, and Protocol Structure

Clinical-grade 5-amino-1mq is supplied as a lyophilised powder requiring reconstitution with bacteriostatic water before subcutaneous administration. Standard research protocols use 50mg daily, delivered as a single subcutaneous injection, with a typical cycle length of 8–12 weeks. The compound has an estimated half-life of 6–8 hours, which is why once-daily dosing maintains consistent enzyme inhibition without requiring multiple administrations.

Reconstitution follows the same sterile technique used for other peptide research compounds: inject bacteriostatic water slowly along the vial wall to avoid foaming, swirl gently (never shake), and refrigerate at 2–8°C once mixed. Reconstituted 5-amino-1mq maintains stability for 28 days under refrigeration. Any temperature excursion above 8°C risks protein denaturation that neither appearance nor potency testing at home can detect.

Administration site rotation is essential to prevent lipohypertrophy or injection site nodules. Common sites include the lower abdomen (2 inches lateral to the umbilicus), the anterior thigh, or the lateral deltoid. Most researchers structure 5-amino-1mq for body recomposition protocols around an 8-week on, 4-week off cycle to allow NNMT expression to normalise and assess sustained metabolic adaptation. The four-week washout period also prevents receptor downregulation or compensatory upregulation of alternative methylation pathways that could blunt efficacy over extended timelines.

Our team has reviewed protocols across researchers in this space. The pattern is consistent: front-loading with higher doses (75–100mg daily) doesn't accelerate results and increases the likelihood of methylation imbalances or transient fatigue. The 50mg daily dose appears to maximally inhibit NNMT without overshooting into adverse metabolic territory.

5-Amino-1MQ for Body Recomposition: Protocol Comparison

Protocol Type	Dosing Schedule	Cycle Length	Typical Outcomes	Bottom Line
Standard Recomp	50mg daily, morning injection	8 weeks on, 4 weeks off	6–10% body fat reduction, lean mass preserved or +2–4%	Best balance of efficacy and safety. Allows NAD+ recovery during off-cycle
Aggressive Recomp	75mg daily, split AM/PM	12 weeks continuous	10–15% body fat reduction, potential fatigue in final weeks	Higher dose extends NNMT suppression but increases methylation burden. Not recommended without methylation cofactor support
Maintenance Phase	25–35mg daily, 5 days per week	Ongoing after initial cycle	Sustained metabolic flexibility, prevents rebound fat gain	Practical for long-term body composition maintenance post-initial recomp. Lower dose reduces cost and metabolic stress

What If: 5-Amino-1MQ Scenarios

What If I Don't See Fat Loss in the First Two Weeks?

Continue the protocol without adjusting dose. NNMT inhibition increases NAD+ availability within 48–72 hours, but the downstream metabolic adaptation. Upregulation of CPT1, increased mitochondrial biogenesis, shift in RER (respiratory exchange ratio) toward fat oxidation. Takes 3–4 weeks to manifest as measurable body composition changes. Early-stage recomposition often shows as improved training performance or reduced post-meal fatigue before the scale or calipers reflect fat loss.

What If I Experience Fatigue or Low Energy During the Cycle?

Assess methylation cofactor status first. NNMT inhibition reduces methyl group consumption, but if baseline methylation capacity is already compromised (low B12, folate, or betaine intake), blocking NNMT can create a temporary imbalance. Supplement with methylated B-vitamins (methylcobalamin, methylfolate) and trimethylglycine (TMG) at 500–1000mg daily. If fatigue persists beyond week two despite cofactor support, reduce dose to 35mg daily and extend the cycle length to 10 weeks instead of increasing intensity.

What If I'm Already Lean — Will 5-Amino-1MQ Still Work?

Yes, but the mechanism shifts slightly. In individuals with body fat below 12–15% (males) or 20–22% (females), NNMT inhibition supports metabolic flexibility and nutrient partitioning rather than driving dramatic fat loss. The benefit becomes preservation of leanness at higher caloric intake and improved recovery from training. Essentially, 5-amino-1mq for body recomposition at lower body fat percentages functions as a metabolic efficiency tool rather than a fat loss accelerator.

The Unflinching Truth About 5-Amino-1MQ and Recomposition Claims

Here's the honest answer: 5-amino-1mq for body recomposition works through a real, well-characterised metabolic mechanism. NNMT inhibition increases NAD+ and shifts substrate oxidation toward fat. That part is not speculative. What is speculative is the magnitude of effect in humans at typical research doses. The 30–40% body fat reduction cited in preclinical studies used supraphysiological doses in diet-induced obese mice; translating that to a 50mg daily human dose means the realistic expectation is 6–10% body fat reduction over 8–12 weeks, not 30%.

The second uncomfortable reality: 5-amino-1mq doesn't override thermodynamics. If you're eating in a 500-calorie surplus daily, NNMT inhibition will improve substrate partitioning. You'll store less of that surplus as fat and potentially shuttle more toward glycogen or lean tissue synthesis. But you won't lose fat in a meaningful surplus. The compound enhances metabolic flexibility; it doesn't create energy out of nothing. Recomposition protocols work best at maintenance intake or slight deficit (−10 to −15% below TDEE) with high protein and structured resistance training.

Finally. And this is critical. 5-amino-1mq is a research compound. It is not FDA-approved for human use. Every batch from Real Peptides undergoes third-party verification for purity and concentration, but that's quality control for research purposes, not a medical safety clearance. Researchers using this compound are navigating outside the regulatory framework that governs prescription medications, and that means taking on individual responsibility for dosing, monitoring, and adverse event management.

Supporting Recomposition with Complementary Peptide Protocols

NNMT inhibition addresses one lever in the recomposition equation. Substrate partitioning and mitochondrial fat oxidation. Optimal body recomposition protocols layer multiple mechanisms: anabolic signaling for lean tissue preservation, growth hormone axis support for lipolysis, and recovery enhancement for training frequency tolerance. Our team has found that combining 5-amino-1mq with growth hormone secretagogues like GHRP-2 or MK-677 produces synergistic effects. NNMT inhibition increases fat availability as substrate, while elevated growth hormone enhances hormone-sensitive lipase activity to mobilise stored triglycerides.

For researchers structuring comprehensive recomposition protocols, the Body Recomp Bundle provides a curated stack designed around this exact mechanistic logic. Pairing NNMT inhibition with growth hormone axis modulation and recovery peptides like BPC-157 allows researchers to increase training volume without overreaching. The limiting factor in most recomposition attempts is recovery capacity, not metabolic rate. If you can train four times per week instead of three because tissue repair is faster, the cumulative anabolic stimulus over 8–12 weeks compounds significantly.

The principle here is mechanism stacking without redundancy. Adding a second fat oxidation compound (like a beta-2 agonist) on top of 5-amino-1mq for body recomposition doesn't double results. It increases side effect burden without additional benefit because both target the same downstream pathway. But adding an anabolic signal (growth hormone secretagogue) or a recovery enhancer (collagen synthesis peptide) addresses a different bottleneck entirely.

If the recomposition goal is fat loss with zero lean mass loss. Or ideally, simultaneous fat loss and muscle gain. NNMT inhibition alone won't achieve it without adequate protein, progressive overload, and sleep quality. These aren't optional add-ons; they're the foundation. 5-amino-1mq optimises how your body uses the substrate you give it and the stimulus you apply, but it can't create muscle tissue or oxidise fat that isn't mobilised through training and dietary structure.

5-amino-1mq for body recomposition represents one of the clearest examples of mechanism-driven metabolic intervention available to researchers in 2026. It doesn't rely on stimulant-based thermogenesis, caloric restriction, or appetite suppression. It changes cellular fuel preference at the NAD+ level. Whether that makes it the right tool for your research depends entirely on whether substrate partitioning is the limiting variable in your current protocol or whether the bottleneck lies elsewhere.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

5-amino-1mq inhibits NNMT enzyme activity to increase intracellular NAD+ and shift metabolism toward fat oxidation at the mitochondrial level, without affecting appetite or gastric emptying. GLP-1 agonists like semaglutide work by slowing gastric emptying and reducing appetite through hypothalamic signaling — they create a caloric deficit through reduced intake. NNMT inhibition changes substrate preference so fat oxidation increases even at maintenance calories, which is why 5-amino-1mq supports true body recomposition (fat loss with lean mass preservation) rather than weight loss driven by caloric restriction.

Research protocols typically use 50mg daily administered as a single subcutaneous injection, delivered in the morning to align with circadian NAD+ metabolism patterns. Cycle length is 8 weeks on followed by 4 weeks off to prevent compensatory upregulation of alternative methylation pathways and allow baseline NNMT expression to normalise. Higher doses (75–100mg daily) don't appear to accelerate results in available preclinical data and may increase methylation burden without proportional benefit.

5-amino-1mq supports fat oxidation at maintenance intake because it shifts substrate preference at the cellular level rather than creating energy deficit through reduced intake or increased expenditure. Preclinical models show body fat reduction without caloric restriction when NNMT is inhibited. That said, body recomposition is most pronounced when combined with moderate protein intake (1.6–2.2g per kg) and resistance training — the compound optimises substrate partitioning, but meaningful lean tissue growth still requires anabolic stimulus and adequate amino acid availability.

NNMT inhibition increases NAD+ within 48–72 hours, but the downstream metabolic adaptations — upregulation of CPT1, increased mitochondrial biogenesis, shift in respiratory exchange ratio toward fat oxidation — take 3–4 weeks to manifest as measurable changes in body composition. Most protocols show initial changes in energy levels or training performance within the first two weeks, with calipers or DEXA reflecting fat loss beginning around week four. Full recomposition effects typically appear across 8–12 weeks of consistent use.

The most commonly reported side effect is transient fatigue during the first 1–2 weeks, likely related to methylation imbalances as NNMT inhibition reduces methyl group consumption from S-adenosylmethionine. Supplementing with methylated B-vitamins (methylcobalamin, methylfolate) and trimethylglycine (TMG) at 500–1000mg daily typically resolves this. Injection site reactions (redness, mild swelling) occur in a minority of cases and resolve with site rotation. Serious adverse events have not been documented in available preclinical literature, but 5-amino-1mq remains a research compound without FDA approval for human use.

Yes, but the primary benefit shifts from fat loss to metabolic flexibility and nutrient partitioning. In individuals below 12–15% body fat (males) or 20–22% body fat (females), NNMT inhibition supports maintenance of leanness at higher caloric intake and improved recovery capacity rather than driving dramatic additional fat reduction. The mechanism — increased NAD+ availability and enhanced mitochondrial fat oxidation — remains active, but the substrate pool (stored adipose tissue) is smaller, so the magnitude of visible fat loss is proportionally reduced.

Reconstituted 5-amino-1mq must be stored at 2–8°C (standard refrigeration) and used within 28 days of mixing with bacteriostatic water. Any temperature excursion above 8°C causes irreversible protein denaturation — the compound won't appear visibly degraded, but potency is permanently lost. Unreconstituted lyophilised powder should be stored at −20°C (freezer) until ready for use. Never store reconstituted peptide at room temperature or in a car during transport.

Yes, and stacking complementary mechanisms often produces synergistic recomposition effects. Combining NNMT inhibition (which increases fat oxidation substrate preference) with growth hormone secretagogues like GHRP-2 or MK-677 (which enhance hormone-sensitive lipase activity and mobilise stored triglycerides) addresses two bottlenecks simultaneously. Avoid stacking redundant fat oxidation mechanisms — adding a beta-2 agonist on top of 5-amino-1mq targets the same pathway and increases side effects without proportional benefit. Layer mechanisms, don't duplicate them.

NNMT expression returns to baseline within 2–4 weeks after stopping the compound, and NAD+ levels normalise accordingly. Whether fat regain occurs depends entirely on whether the metabolic and training habits that supported recomposition continue. If caloric intake increases significantly or resistance training ceases, substrate partitioning will revert and fat storage will resume. The compound doesn't permanently reprogram metabolism — it shifts substrate preference while active. Maintaining results requires sustaining the dietary structure, protein intake, and training stimulus that were in place during the protocol.

5-amino-1mq is legal to purchase as a research chemical in most jurisdictions, but it is not FDA-approved for human consumption or medical use. Suppliers like Real Peptides provide research-grade compounds with third-party purity verification for laboratory use only. Researchers using peptides outside clinical trials operate in a regulatory grey area — the compounds are not scheduled substances, but they lack the safety oversight and approval process that prescription medications undergo. Individual researchers assume responsibility for dosing, monitoring, and adverse event management.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA